JPMorgan Chase & Co. Has $44.82 Million Position in Revvity Inc. $RVTY

JPMorgan Chase & Co. raised its holdings in Revvity Inc. (NYSE:RVTY) by 15.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 511,360 shares of the company’s stock after acquiring an additional 67,662 shares during the quarter. JPMorgan Chase & Co. owned about 0.44% of Revvity worth $44,821,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. AQR Capital Management LLC lifted its stake in shares of Revvity by 5.2% in the 1st quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock valued at $883,000 after purchasing an additional 420 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Revvity by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock worth $1,246,000 after buying an additional 744 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Revvity by 102.0% during the 1st quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock worth $7,343,000 after acquiring an additional 35,048 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Revvity by 45.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock worth $64,232,000 after acquiring an additional 189,871 shares in the last quarter. Finally, Focus Partners Wealth raised its stake in shares of Revvity by 13.0% in the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock valued at $744,000 after acquiring an additional 811 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group started coverage on Revvity in a research report on Tuesday, December 9th. They set a “neutral” rating and a $105.00 target price for the company. TD Cowen reaffirmed a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Bank of America lowered shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 target price on the stock. in a research note on Monday, December 15th. Wells Fargo & Company boosted their target price on shares of Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on Revvity from $100.00 to $105.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 3rd. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $113.67.

Key Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Zacks Research raised Revvity’s near-term and FY2026 estimates (Q2 2026 to $1.31, Q3 2026 to $1.34 and FY2026 to $5.36), reflecting stronger-than-expected momentum and aligning with company guidance; higher FY2026 estimates support revenue/earnings beat narratives. MarketBeat: Revvity estimates
• Positive Sentiment: Investors are also responding to coverage of Revvity’s strong Q4 beat and upbeat 2026 outlook — the company reported quarterly EPS and revenue above consensus and provided FY2026 guidance that analysts view as constructive for near-term growth. How Investors May Respond To Revvity Strong Q4 Beat
• Neutral Sentiment: Third‑party comparisons and sector context (e.g., Progyny vs. Revvity) are circulating but are unlikely to materially move the stock absent new company-specific guidance or results. Financial Comparison: Progyny vs. Revvity
• Negative Sentiment: Zacks trimmed several 2027 estimates (Q1 2026 cut to $1.03, Q2/Q3 2027 cuts and FY2027 reduced to $5.90 from $5.97), which temper longer‑term growth expectations and could cap multiple expansion if analysts continue to lower longer-dated forecasts. MarketBeat: Revvity estimates

Revvity Stock Up 1.4%

RVTY stock opened at $98.97 on Friday. The business’s 50-day simple moving average is $103.27 and its 200 day simple moving average is $96.32. The company has a quick ratio of 1.40, a current ratio of 1.68 and a debt-to-equity ratio of 0.36. The company has a market cap of $11.06 billion, a PE ratio of 47.58, a price-to-earnings-growth ratio of 2.07 and a beta of 1.07. Revvity Inc. has a twelve month low of $81.36 and a twelve month high of $120.39.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. Revvity had a return on equity of 7.92% and a net margin of 8.45%.Revvity’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.42 EPS. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s payout ratio is 13.46%.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.